ErbB2 overexpression in breast cancer is always associated with poor patient prognosis [37, 38], but ErbB2 targeted therapies have significantly improved patient survivals, hence confirming this receptor tyrosine kinase as the pivotal therapeutic target for intervention in the treatment of ErbB2-positive breast cancers. Here, NTRK1 is linked to breast carcinoma.